SPORE in Breast Cancer

乳腺癌中的孢子

基本信息

批准号：
9791049
负责人：
Ingrid A Mayer
金额：
$ 221.81万
依托单位：
VANDERBILT UNIVERSITY MEDICAL CENTER
依托单位国家：
美国
项目类别：
财政年份：
2003
资助国家：
美国
起止时间：
2003-08-07 至 2024-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9791049
关键词：
Academic Medical Centers Address Advocate Antigen Presentation Antigen Targeting Area Atlases Award Basic Science Bioinformatics Biometry Breast Breast Cancer Patient Breast Cancer Risk Factor CDK4 gene Cancer Center Carboplatin Cells Clinical Clinical Investigator Clinical Research Clinical Trials Collaborations DNA Damage Databases Development Diagnosis Disease Drug Combinations ERBB2 gene Ensure Estrogen Antagonists Estrogen Receptors Estrogens Evaluation Fibroblast Growth Factor Receptors Fulvestrant Funding Future Genomics Goals Health Human Human Resources Immune Immune Evasion Immune response ImmunoPET Immunophenotyping Immunotherapeutic agent Immunotherapy In Vitro Individual Informatics International Investigation MEK inhibition MEKs Mammary gland Mediating Metastatic breast cancer Modeling Molecular Target Mutate Myelogenous Neoplasms PDCD1LG1 gene Paclitaxel Pathology Patient Selection Patient-Focused Outcomes Patients Pharmaceutical Preparations Poly(ADP-ribose) Polymerases Positron-Emission Tomography Refractory Research Personnel Research Project Grants Resistance Resource Sharing Resources Solid Neoplasm Testing Therapeutic Therapeutic Clinical Trial Therapeutic Intervention Tissues Translational Research Tumor Immunity Up-Regulation Validation Woman Work anti-PD-L1 anticancer research base biomarker identification cancer immunotherapy cancer subtypes career checkpoint therapy chemotherapy clinical investigation drug discovery experience hormone therapy immunoregulation improved improved outcome inhibitor/antagonist innovation innovative technologies insight malignant breast neoplasm meetings member men molecular targeted therapies mouse model multidisciplinary new therapeutic target outcome forecast programs recruit resistance mechanism response response biomarker triple-negative invasive breast carcinoma tumor tumor microenvironment

项目摘要

PROJECT SUMMARY/ABSTRACT: OVERALL This is the third competing renewal application of the Vanderbilt-Ingram Cancer Center (VICC) SPORE in Breast Cancer. Using the well-established framework of a very active and strong multidisciplinary VICC Breast Cancer Program that is robustly supported by the SPORE mechanism, we have made significant progress in our current project period. Our highly successful Developmental Research Projects (DRP) and Career Enhancement Programs (CEP) continue to catalyze new ideas and new investigators in translational breast cancer research, including two projects in this continuing renewal. We are uniquely poised to complete the proposed work and to be even more productive in the years to come, thanks to an exceptional multidisciplinary program and established productive collaborations with other Breast Cancer Programs and SPOREs, as well as national and international collaborations. Our overall goal remains the same: To conduct collaborative, multidisciplinary and mechanism-based translational research that will have the highest possible impact for women and men with or at risk for breast cancer. After significant planning and internal and external advisory board evaluation, we propose four bi-directional translational projects addressing basic, translational and clinical research questions of importance in human breast cancer; Projects 1 and 2 are continuation projects, Projects 3 and 4 are new projects that have evolved from two CEP awards in the current funding cycle: Project 1 - Mechanisms of Resistance to Endocrine Therapy in ER+ Breast Cancer; Project 2 - Strategies to Improve Outcomes for TNBC Patients Integrating Subtype-specific Genomic and Immune-based Discoveries; Project 3 - Targeting the DNA Damage Response in Breast Cancer; Project 4 - Targeting Antigen Presentation to Improve Immunotherapy Responses in Breast Cancer. The application also includes DRP and CEP, and four highly integrated shared core resources: Administration and Engagement, Biostatistics and Bioinformatics, Pathology and Tissue Informatics, and Immunophenotyping. The cores bring innovative technology and resources, including additional personnel with project-specific expertise, to the overall VICC Breast SPORE Program and do not duplicate pre- existing shared resources available at VICC or Vanderbilt University Medical Center (VUMC). With a focus on human endpoints, six interventional therapeutic clinical trials are associated with the highly translational projects in this proposal, all based on extensive collaboration between world-class basic and clinical investigators. We have firmly established a true multidisciplinary team that successfully implements innovative clinical trials to test hypotheses that result from in vitro and patient studies, and that will continue to have productive translational collaborations with other Breast Cancer Programs and SPOREs as well as national and international groups.

项目概要/摘要：总体这是范德比尔特-英格拉姆癌症中心 (VICC) SPORE 在乳腺领域的第三次竞争性更新申请癌症。使用非常活跃且强大的多学科 VICC 乳腺癌的完善框架在 SPORE 机制的大力支持下，我们目前已经取得了重大进展项目期。我们非常成功的发展研究项目 (DRP) 和职业提升计划（CEP）继续促进转化乳腺癌研究中的新想法和新研究者，在这个持续更新中包括两个项目。我们完全准备好完成拟议的工作并得益于卓越的多学科计划和与其他乳腺癌计划和 SPORE 以及国家和地区建立了富有成效的合作国际合作。我们的总体目标保持不变：开展协作、多学科和基于机制的转化研究将对患有或患有以下疾病的女性和男性产生尽可能最大的影响有患乳腺癌的风险。经过重大规划和内部和外部顾问委员会评估后，我们提出四个双向转化项目，解决基础、转化和临床研究问题对人类乳腺癌具有重要意义；项目1和2是延续项目，项目3和4是新项目在当前资助周期中由两个 CEP 奖项演变而来的项目：项目 1 - 机制 ER+乳腺癌对内分泌治疗的耐药性；项目 2 - 改善 TNBC 成果的策略患者整合亚型特异性基因组和基于免疫的发现；项目 3 - 靶向 DNA 乳腺癌的损伤反应；项目 4 - 靶向抗原呈递以改善免疫治疗乳腺癌的反应。该应用还包括DRP和CEP，以及四个高度集成的共享核心资源：管理和参与、生物统计学和生物信息学、病理学和组织信息学和免疫表型。这些核心带来了创新技术和资源，包括额外的具有项目特定专业知识的人员参与整个 VICC 乳房 SPORE 计划，并且不会重复预 VICC 或范德比尔特大学医学中心 (VUMC) 现有的共享资源。重点关注人类终点，六项介入治疗临床试验与高度转化项目相关在该提案中，所有这些都基于世界一流的基础和临床研究人员之间的广泛合作。我们牢固地建立了一支真正的多学科团队，成功实施了创新的临床试验来测试来自体外和患者研究的假设，并将继续产生富有成效的转化与其他乳腺癌计划和 SPORE 以及国家和国际团体的合作。